Author: Vivian Xie 3rd July 2026

There is no arguing with India’s reputation as an international drug manufacturing powerhouse; as well as being the world's largest provider of generic drugs, [1] the country also accounts for 60% of global vaccine. However, in order to maintain its place at the top, the country’s expansive manufacturing capacity requires continuous innovation in both formulation science and manufacturing technology. Historically, ingredient sourcing and equipment procurement have operated as separate functions within pharma organisations. However, as quality-by-design (QbD) principles [2] have gained popularity, thanks to endorsement from regulatory authorities, companies have begun to take a more holistic view of continuous manufacturing.

It’s this more integrated view of the Indian pharma landscape which will drive this year’s edition of CPHI & PMEC India, taking place over four days across two venues this November. This dual-event format comes as a strategic response to the pharmaceutical industry's requirement for integrated solutions spanning the entire value chain, from active pharmaceutical ingredient (API) development through to final packaging and distribution. Formulation chemistry and manufacturing capability have never been more closely aligned. Read on to learn why CPHI & PMEC India 2026 is the show for pharma leaders looking to meet the moment head-on.

Unpacking the Advantages of Our Dual-Event Architecture

By splitting CPHI & PMEC India across two venues, this year’s show will better reflect the inherent complexity of the pharma manufacturing value chain. CPHI India, which takes place at Delhi’s IICC, concentrates on formulation science, excipient technology, API development and ingredient innovation. Meanwhile, at IEML in Greater Noida, PMEC India will highlight manufacturing equipment, packaging solutions and process technology.

From a planning perspective, this dual-event format lets pharmaceutical organisations deploy cross-functional teams effectively across both venues, allowing for specialised engagement with suppliers and technology providers within each domain. This parallel engagement model reduces the time constraints typically associated with exhibitions of this size, giving attendees more time to carefully consider their potential partnerships.

Furthermore, the two venues are less than an hour away from each other, with a regular shuttle bus between the two ensuring a smooth event experience for all attendees. This will also facilitate immediate cross-referencing between ingredient capabilities and manufacturing requirements. When formulation scientists identify novel excipients or API sources at the IICC, manufacturing engineers can immediately assess equipment compatibility and process implications at IEML. This real-time integration accelerates decision-making processes and reduces the risk of misalignment between formulation development and manufacturing capability, a common source of delays [3] in pharmaceutical product development.

Aligning Ingredient Sourcing With Manufacturing Technology

Simply put, there is no way to separate specialised pharmaceutical ingredients from the manufacturing methodology which enables them to be made. Certain excipients require specific processing conditions, with some APIs demanding specialised containment and novel delivery systems necessitating adapted equipment configurations. CPHI & PMEC India’s dual-event format allows industry professionals the chance to explore these interdependencies firsthand.

Consider the development of orally disintegrating tablets (ODTs), which require both specialised excipients (superdisintegrants, taste-masking agents and rapidly dissolving binders) and adapted manufacturing equipment (low-compression-force tablet presses and moisture-controlled environments). A pharmaceutical organisation developing ODT formulations can identify appropriate excipient suppliers at one venue, simultaneously evaluating compatible manufacturing equipment at the other. This has the potential to reduce development timelines and minimise the risk of incompatibilities in formulation manufacturing that would otherwise require costly reformulation efforts.

Similarly, the growing adoption of continuous manufacturing technologies creates new requirements for ingredient characteristics. Continuous direct compression, for instance, demands excipients with superior flow properties and consistently distributed particle size compared to traditional batch processing. By attending both exhibitions, manufacturers can align their ingredient specifications with equipment capabilities, ensuring that sourcing decisions are supported by, rather than constrained by, wider manufacturing strategy.

Under mounting pressure to develop more sophisticated formulations, pharma organisations need to find efficient opportunities to enhance bioavailability, improve patient compliance and address complex therapeutic challenges. CPHI & PMEC India serves as a critical platform for these sorts of innovations and far more besides, granting direct access to suppliers and allowing scientists time to conduct key evaluations of competing technologies.

Furthermore, the show addresses the growing demand for high-potency API handling and containment solutions. As oncology and immunology therapeutics become increasingly dominant over development pipelines, manufacturers will need to integrate specialised ingredients and handling protocols that meet stringent occupational exposure limits. CPHI & PMEC India gives suppliers with demonstrated expertise in high-potency compound management a place to meet, share knowledge, and make meaningful partnerships in this technically demanding domain.

Solving Manufacturing, Packaging and Equipment Needs

If pharmaceutical development is driven by developing formulations, a company’s manufacturing capability will determine its commercial viability. PMEC India addresses the critical equipment and technology requirements that make efficient, compliant and scalable pharmaceutical production possible. As the part of the event dedicated to pharma equipment, PMEC India provides comprehensive access to international machinery suppliers across all manufacturing unit operations.

Many regulatory agencies, including the Indian Pharmaceutical Association, are actively encouraging the adoption of continuous manufacturing [5] as a means of enhancing supply chain resilience. Similarly, cleanroom technology is seeing increasing demand as a means of optimising facility design and improving contamination control efforts. Measures like these directly impact product quality, regulatory compliance and operational costs. The exhibition provides access to suppliers offering validated solutions for particulate control, microbial contamination prevention and environmental parameter monitoring, all essential components of current Good Manufacturing Practice compliance. International cleanroom standards [6] establish the technical requirements that exhibiting suppliers must address, ensuring that manufacturers can identify solutions meeting globally recognised specifications.

Packaging technology represents another focal area of PMEC India, addressing challenges in product protection, serialisation and patient-centric design. With global implementation of track-and-trace requirements and increasing emphasis on medication adherence, packaging has evolved from a purely protective function to an integrated component of pharmaceutical product strategy. The exhibition enables manufacturers to evaluate serialisation technologies, smart packaging solutions and sustainable packaging alternatives within a concentrated timeframe.

Regulatory and Quality Considerations

Pharmaceutical manufacturing operates within stringent regulatory frameworks that oversee ingredient sourcing, equipment qualification and process validation. The shows which make up CPHI & PMEC India will make regulatory compliance more attainable than ever, bringing together only suppliers with demonstrated cGMP adherence and established track records of regulation.

Those attending this year’s show to evaluate potential ingredient suppliers will need to assess regulatory filing support, drug master file availability and quality system maturity. Similarly, equipment suppliers should be able to demonstrate their validation support capabilities, with design qualification documentation and evidence of compliance with the relevant international standards. The event’s split format enables direct assessment of supplier quality systems and regulatory expertise in accordance with WHO guidance, offering a seamless experience that would be near-impossible to evaluate through remote engagement.

The pharmaceutical manufacturing sector's complexity demands integrated approaches that span formulation science, manufacturing technology and supply chain management. CPHI & PMEC India provides a comprehensive platform for global pharma organisations to address these multifaceted requirements. Whether you’re looking to optimise ingredient sourcing decisions against manufacturing capabilities, evaluate emerging technologies across the entire value chain, or establish strategic connections, you’ll find it in this unique environment that has been specifically designed for knowledge sharing, technology evaluation and partnership development.